Submit a manuscript Sign up for article alerts Contact us Support

About Molecular Pain

This page includes information about the aims and scope of Molecular Pain, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.

Aims & scope

Molecular Pain considers manuscripts in pain research at the cellular, subcellular and molecular levels. Molecular Pain provides a forum for molecular pain scientists to communicate their research findings in a targeted manner to others in this important and growing field.

The field of molecular pain research has been rapidly expanding in recent years, and has great promise for the identification of highly specific and effective targets for the treatment of intractable pain.

Molecular pain research addresses physiological and pathological pain at all levels whilst integrating pain research with molecular biology, genomics, proteomics, modern electrophysiology and neurobiology.

Although several existing journals publish articles on classical pain research, none are specifically dedicated to molecular aspects of the field.

Open access

All articles published by Molecular Pain are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

Authors of articles published in Molecular Pain are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

Open access publishing is not without costs. Molecular Pain therefore levies an article-processing charge of £1570/$2675/€1985 for each article accepted for publication. If the submitting author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.

Indexing services

All articles published in Molecular Pain are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Molecular Pain include:

  • Biological Abstracts
  • BIOSIS
  • CAS
  • Citebase
  • Current contents
  • DOAJ
  • Embase
  • Google Scholar
  • Index Copernicus
  • MEDLINE
  • OAIster
  • PsycINFO
  • PubMed
  • PubMed Central
  • Science Citation Index Expanded
  • Scopus
  • SOCOLAR
  • Zetoc

The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).

The full text of all research articles published by BioMed Central is also available on SpringerLink.

Molecular Pain is tracked by Thomson Reuters (ISI) and has an Impact Factor of 3.53.

Publication and peer review process

Criteria for publication

Molecular Pain considers the following types of articles:

  • Research: reports of data from original research. We anticipate that a research article will contain no more than 8 figures. Authors should try to limit the Background and Discussion sections to no more than 1000 and 1500 words respectively.
  • Review: comprehensive, authoritative descriptions of any subject within the scope of the journal. Enquiries to the Molecular Pain Editors regarding the suitability of a proposed review prior to submission are encouraged.
  • Commentary: short, focussed and opinionated articles on any subject within the scope of the journal. These articles are usually related to a contemporary issue, such as recent research findings. Enquiries to the Molecular Pain Editors regarding the suitability of a subject area prior to submission are encouraged.
  • Conflicting report: brief reports of data from original research that conflict with a recent key finding published in a high-impact, broad-scope journal, such as Science, Nature and Cell. A conflicting report can be a negative result that nulls the previous key finding. The main purpose of a conflicting report is to challenge an existing finding and to provide a different and/or opposite opinion or interpretation on a dominant view. This encourages scientific debates and helps to correct potential mistakes of a major article published in a high-impact journal. For a conflicting report, authors must clearly acknowledge the previous key finding, followed by their conflicting results. The format and length of a conflicting report are similar to that of a Molecular Pain short report.
  • Meeting report: a short description of a conference that the author has attended, which focuses on the key developments presented and discussed at the meeting.
  • Methodology: present a new experimental method, test or procedure. The method described may either be completely new, or may offer a better version of an existing method.
  • Short report: brief reports of data from original research. A complex figure with several panels is encouraged.

Peer-review policies

Manuscripts submitted to Molecular Pain are assigned to a Deputy Editor, who appoints two peer reviewers. Based on the reviews, the Deputy Editor will make a recommendation to the co-Editors-in-Chief for rejection, revision or acceptance. It is expected that the review period will not exceed three weeks. Our electronic submission process is designed to facilitate rapid publication.

Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Molecular Pain, a personalized section of the site.

Reprints

High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.

Supplements

Molecular Pain will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.

Editorial policies

All manuscripts submitted to Molecular Pain should adhere to BioMed Central's editorial policies.

Citing articles in Molecular Pain

Articles in Molecular Pain should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Mol Pain [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Mol Pain 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Why publish your article in Molecular Pain?

High visibility

Molecular Pain's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.

Speed of publication

Molecular Pain offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Molecular Pain, BioMed Central and PubMed Central and will also be included in PubMed.

Flexibility

Online publication in Molecular Pain gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Molecular Pain are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Molecular Pain's pages and on the BioMed Central homepage.

In addition, articles published in Molecular Pain may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Molecular Pain. A list of articles recently press-released by journals published by BioMed Central is available here.

Authors of articles published in Molecular Pain retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).

For further information about the advantages of publishing in a journal from BioMed Central, please click here.